Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients

阿达木单抗 医学 银屑病性关节炎 银屑病 内科学 白细胞介素17 白细胞介素23 胃肠病学 肿瘤坏死因子α 免疫学 细胞因子
作者
Luca Mastorino,Sara Susca,Caterina Cariti,Niccolò Sliquini,Anna Verrone,Elena Stroppiana,M. Ortoncelli,Paolo Dapavo,Simone Ribero,Pietro Quaglino
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:37 (9): 1848-1853 被引量:16
标识
DOI:10.1111/jdv.19135
摘要

Many national guidelines at the European level recommend first-line therapy based on the anti-TNF-alpha adalimumab for treatment of psoriasis and psoriatic arthritis, mainly for economic reasons. Consequently, patients being treated with newer IL-17 and IL-23 inhibitors underwent previous unsuccessful first-line adalimumab-based therapy.Evaluate the efficacy and safety of IL-17 and IL-23 inhibitors after treatment with adalimumab compared to adalimumab-naive psoriatic patients.We retrospectively analysed 1053 psoriatic patients treated with anti-IL17 and anti-IL23 agents, which included 68 and 24 adalimumab-experienced and 399 and 260 bio-naive patients. Efficacy was assessed with mean PASI, PASI90, PASI100, and <3.Concerning the achieving of PASI100, PASI90 and PASI < 3 in patients treated with anti-IL17 agents, no significant differences were observed between adalimumab-experienced and bio-naive patients. In patients treated with an anti-IL-23 agent, a faster response was observed in bio-naive patients, with PASI < 3 significantly higher than ADA-experienced patients at 16 weeks (77% vs. 58% p = 0.048). In a sub-analysis that evaluated the performance of anti-IL17 and anti-IL23 agents in adalimumab-experienced patients with a history of secondary failure, no significant differences were found. In multivariate analysis of PASI100, only anti-IL-17 therapy appeared to have a negative impact at 52 weeks (OR: 0.54 p = 0.04) independently of previous treatment. For PASI90, type of treatment and bio-naïve status did not seem to have an impact at any time point.Anti-IL 23 and anti-IL 17 agents are not significantly different in terms of efficacy in bio-naive patients or as second-line therapy after failure with a biosimilar or originator adalimumab.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
爱吃草莓和菠萝的吕可爱完成签到,获得积分10
2秒前
缥缈一刀发布了新的文献求助10
4秒前
小地蛋完成签到 ,获得积分10
5秒前
感谢大哥的帮助完成签到 ,获得积分10
5秒前
614521完成签到,获得积分10
7秒前
111完成签到,获得积分10
8秒前
王先生完成签到 ,获得积分10
8秒前
9秒前
殊荣完成签到,获得积分10
10秒前
JAMA兜里揣完成签到,获得积分10
10秒前
lalala完成签到 ,获得积分10
12秒前
王三歲完成签到,获得积分10
13秒前
你的背包完成签到,获得积分10
13秒前
Yang应助快乐枫采纳,获得10
14秒前
冷傲的如柏完成签到,获得积分10
15秒前
量子星尘发布了新的文献求助10
17秒前
Z_yiming完成签到,获得积分10
17秒前
刘雪晴完成签到 ,获得积分10
17秒前
CCL完成签到,获得积分10
18秒前
缥缈一刀完成签到,获得积分10
19秒前
yar应助坚强幼晴采纳,获得10
19秒前
茶茶完成签到,获得积分0
20秒前
斑点完成签到,获得积分10
20秒前
24秒前
鱼儿乐园完成签到 ,获得积分10
24秒前
XF完成签到,获得积分20
25秒前
25秒前
木之木完成签到,获得积分0
25秒前
哈哈哈哈完成签到,获得积分10
25秒前
奋斗摩托完成签到,获得积分10
27秒前
CC完成签到,获得积分10
27秒前
桃子e完成签到 ,获得积分10
28秒前
zhaoli完成签到 ,获得积分10
29秒前
老唐发布了新的文献求助50
30秒前
藏雨宁完成签到 ,获得积分10
30秒前
Allen完成签到,获得积分10
30秒前
vv完成签到,获得积分10
30秒前
YHX发布了新的文献求助10
31秒前
31秒前
许诺完成签到,获得积分10
32秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038303
求助须知:如何正确求助?哪些是违规求助? 3576013
关于积分的说明 11374210
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029